A B S T R AC T
Background. Agranulocytosis has been reported as a delayedonset complication of rituximab treatment. However, the exact incidence and risk factors of this complication in patients with nephrotic syndrome remain unknown. Methods. Records of 213 rituximab treatments for 114 patients with refractory nephrotic syndrome between February 2006 and April 2013 were reviewed to identify episodes of agranulocytosis (defined as an absolute neutrophil count of <500 mm 3 
).
Results. Eleven episodes of agranulocytosis were detected in 11 patients. Median time of onset of agranulocytosis was 66 days (range, 54-161 days) after rituximab treatment. Nine patients experienced acute infections and received antibiotics. All but one patient received granulocyte colony-stimulating factor. Agranulocytosis resolved in all cases within a median of 3 days. The incidence of agranulocytosis was 9.6% in total patients and 5.2% in all treatments. Median age of the 11 patients who developed agranulocytosis was 6.4 years at the first rituximab treatment, significantly younger than the median age of the 103 patients who did not (median, 12.5 years; P = 0.0009). Five patients received re-treatment with rituximab. No recurrence of agranulocytosis was observed in any patient.
Conclusions.
It is important to pay extra attention to this clinically serious delayed-onset complication as it may be accompanied by life-threatening infections such as sepsis. Further clinical studies are needed to clarify its pathogenesis.
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I N T R O D U C T I O N
Rituximab is a chimeric monoclonal antibody directed against the cell surface antigen CD20 expressed on B lymphocytes. As it has been proven to be effective in preventing relapses [1] [2] [3] [4] [5] [6] [7] , it is increasingly being used in the treatment of patients with steroid-dependent nephrotic syndrome. While transient infusion-related side effects such as cough, sore throat, dyspnea and fever may occur, the toxicity of rituximab is relatively mild and well tolerated by most patients.
Nonetheless, agranulocytosis, a severe form neutropenia, has been reported to be a delayed-onset complication of rituximab treatment in patients with lymphoma [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and autoimmune diseases [18] [19] [20] [21] . Agranulocytosis usually occurs 1-6 months after rituximab administration and is often selflimiting. However, life-threatening infections can sometimes emerge. To date, there has been a case report of agranulocytosis associated with rituximab in nephrotic syndrome [22] . The exact incidence and risk factors of this complication in patients with nephrotic syndrome remain unknown. Herein, we analyzed all cases of agranulocytosis associated with rituximab treatment for refractory nephrotic syndrome in our center to evaluate the incidence and clinical characteristics of this complication.
M AT E R I A L S A N D M E T H O D S
Records of 213 rituximab treatments administered between February 2006 and April 2013 for 114 patients with refractory nephrotic syndrome were reviewed to identify episodes of agranulocytosis, defined as Grade 4 neutropenia (an absolute neutrophil count of <500 mm Indication of rituximab treatment was refractory steroiddependent nephrotic syndrome (steroid dependence under immunosuppressive agents) or refractory steroid-resistant nephrotic syndrome (failure to go into remission despite a combination of cyclosporine and methylprednisolone pulse therapy). Rituximab was administered at a single dose of 375 mg/m 2 for 205 treatments, two doses of 375 mg/m 2 for one treatment (2-week interval for each infusion) and four doses of 375 mg/m 2 (once a week) for seven treatments. A total of 235 doses of rituximab were administered. To minimize infusion reactions, patients received intravenous methylprednisolone (1-1.5 mg/kg), oral acetaminophen (10 mg/kg, a maximum of 300 mg) and chlorpheniramine maleate (0.04 mg/kg, a maximum of 2 mg), 30 min prior to rituximab infusion. All patients were admitted to our center and were monitored for at least 24 h after rituximab treatment for infusion reactions. Complete blood counts and CD19+ B-cell counts were performed at least once a month until B-cell recovery. When a patient presented with fever at an emergency visit, procedures such as complete blood counts, C-reactive protein test, chest X-ray, urinalysis, blood and urine culture were immediately performed. Rituximab-associated agranulocytosis was defined as an episode during B-cell depletion where CD19+ B-cell count was <1% of total lymphocytes. B-cell recovery was defined as CD19+ B-cell count of equal to or >1% of total lymphocytes. Since January 2012, sulfamethoxazole/trimethoprim has been used at a dose of 5 mg/kg of trimethoprim once every 2 days for B-cell depletion with prophylaxis of pneumocystis jirovecii and bacterial infection.
The data were analyzed with JMP version 9.0 (SAS institute Japan Ltd, Tokyo, Japan). The Mann-Whitney U-test was used for continuous values and the Fisher's exact test for categorical values. Statistical significance was established at P < 0.05.
R E S U LT S
Eleven episodes of agranulocytosis were detected in 11 patients (Table 1) . Eight patients developed agranulocytosis after the first rituximab treatment while three others did so only after the second treatment. With the exception of one patient who received four doses of rituximab (Patient 1), all patients received a single dose. Every patient received one or more immunosuppressive agents at the time of agranulocytosis. Table 2 shows the clinical features of agranulocytosis in the 11 patients. Median time of onset of agranulocytosis was 66 days (range, 54-161 days) after rituximab treatment. Two patients developed agranulocytosis at the same time as B-cell recovery, while nine patients were accompanied by acute infections and received antibiotics. All except one patient received granulocyte colony-stimulating factor (G-CSF). Agranulocytosis resolved in all cases within a median of 3 days.
The incidence of agranulocytosis was 9.6% (11 of the 114 patients) in total patients and 5.2% (11 of the 213 treatments) in total treatments. Table 3 shows the clinical characteristics of patients with and without agranulocytosis. Median age of the 11 patients who developed agranulocytosis was 6.4 years (interquartile range, 4.3-10.2 years) at the first rituximab treatment; significantly younger than the median age of the 103 patients who did not (median, 12.5 years; interquartile range, 4.3-10.2 years; P = 0.0009). Table 4 shows the incidence of agranulocytosis stratified by concomitant immunosuppressive agents. No statistical significance was found among these treatments. Six episodes of agranulocytosis were observed in 129 treatments (4.7%) without the prophylactic use of sulfamethoxazole/trimethoprim, while five episodes were observed in 84 treatments (6.0%) with the use of sulfamethoxazole/trimethoprim (P = not significant).
Five patients (Patient 3, 4, 5, 7 and 9) received re-treatment with rituximab. No recurrence of agranulocytosis was observed in any patient.
D I S C U S S I O N
In this retrospective study, the onset of agranulocytosis was 2-5 months after rituximab treatment and appeared to be associated with infections in most cases. Younger patients were found to be more likely to develop agranulocytosis. Treatment with G-CSF seemed effective. Re-treatment of rituximab was acceptable in all patients. Table 5 shows previous reports of agranulocytosis associated with rituximab treatment in patients with non-Hodgkin lymphoma [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] and autoimmune diseases [18] [19] [20] [21] . The incidence of agranulocytosis was reported as 6.9 and 3.2%, respectively. The higher incidence in patients with lymphoma was probably due to the influence of other chemotherapies. In comparison, the incidence in our study is higher than that of patients with autoimmune diseases, but lower than that of patients with lymphoma.
The risk factors for agranulocytosis after rituximab treatment have so far been investigated mainly in lymphoma patients. Autologous stem-cell transplantation [9, 13] , acquired immunodeficiency syndrome-related lymphoma [10] , previous cytotoxic treatment [11] , intensive chemotherapy [13] , intensive radiotherapy [13] , advanced stage of lymphoma (3 or 4) [13] , multiple doses of rituximab (>4) [11] and FcγR genotypes [16] have all been reported to be risk factors. In our study, a young age at time of rituximab treatment seemed to be risk factor. In our study, even though one patient Further investigation is needed to verify this. While we used G-CSF for our patients, we are aware that its efficacy for rituximab-induced agranulocytosis remains questionable. However, a systematic review of 980 case reports of druginduced agranulocytosis did demonstrate that the use of hematopoietic growth factors resulted in a shorter median duration of neutropenia, and that patients treated with growth factors had significantly lower proportion of infections or fatal complications [23] . A recent review article proposed that the use G-CSF must be considered on a case-by-case basis [24] .
, clinical evidence of bacteremia or septic shock and severe comorbidities such as renal failure, the use of G-CSF may be justifiable.
To date, there are few reports on re-administration of rituximab. One case series from Israel reported a rituximab re-treatment for late-onset neutropenia resulted in recurrent episodes of agranulocytosis in one patient [25] , while another case series reported six patients with re-treatment but had no such recurrence [21] . In our study, none of the patients experienced recurrence of agranulocytosis. Moreover, 3 of the 11 patients developed agranulocytosis only after the second rituximab treatment. Nonetheless, further investigation is required to confirm the safety of rituximab re-treatment for patients with a history of rituximab-associated agranulocytosis.
The exact mechanism of neutropenia associated with rituximab remains poorly understood. Several hypotheses have been proposed, such as the transient production of autoantibodies against neutrophils during immune reconstitution [26] , hyperproliferation of large granular T cells in the bone marrow [27, 28] or viral infection during dysfunctional humoral immunity [29, 30] . In previous reports, neutrophil maturation arrest was revealed by bone marrow aspiration. A direct toxicity of rituximab is less likely since CD20 is not expressed on neutrophils and their precursors. Dunleavy et al. [10] reported a correlation between rapid B-cell recovery and perturbation of stromal cell-derived factor-1 (SDF-1) and neutropenia. Another cytokine influenced by rituximab administration is B-cellactivating factor (BAFF), which plays a role in human B-cell survival, expansion and development. Terrier et al. [31] reported that BAFF levels were undetectable prior to rituximab administration, but increased after treatment and eventually peaked at a time interval that coincided with the occurrence of neutropenia. The fact that two of our patients developed agranulocytosis almost at the same time as B-cell recovery may support these hypotheses, although it is noteworthy that neither SDF-1 nor BAFF was analyzed. Some reports have shown that FcγRIIIa polymorphism was highly associated with the development of late-onset neutropenia [16, 32] . Weissmann-Brenner et al. [33] , who showed a suppression of colony-forming unit growth by plasma of patients with rituximab-induced neutropenia, have proved that circulating antibodies in the plasma may be responsible for leukopenia after rituximab treatment. Again, further investigation is necessary to confirm the exact pathogenesis.
Agranulocytosis was detected in four of our patients by chance, supporting the theory of a primary mechanism. The other seven patients experienced fever prior to detection, suggesting a mechanism secondary to infections. On the other hand, 32 events of bacterial infections were observed in the 114 patients who received rituximab treatments but experienced no agranulocytosis. As such, we think that the cause of agranulocytosis varies from patient to patient.
There are several limitations to our study. First, we do not have information on the maturation of neutrophils as no bone marrow aspirations were performed. Second, as the patients were receiving one or more immunosuppressive agents at the time of agranulocytosis, we cannot rule out the possibility that these agents may have an association with the condition. However, none of our patients developed agranulocytosis before rituximab use despite the use of a similar immunosuppressive menu. This suggests that rituximab is likely to be the main cause of agranulocytosis. Third, the number of patients was relatively small. We need to accumulate more clinical data and information on this complication in future studies.
In conclusion, rituximab use is a potential cause of agranulocytosis for patients with refractory idiopathic nephrotic syndrome. As rituximab use is increasing in such patients, we have to be vigilant of any potential clinically serious delayedonset complication. When a patient with a history of rituximab treatment suffers from fever, we should not rule out the possibility of agranulocytosis as well as serious bacterial infections such as sepsis. At the same time, it is necessary for patients to recognize this complication and visit an emergency clinic as soon as possible upon developing fever. The monitoring of complete blood counts and CD19+ B-cell counts at least once a month after rituximab use until B-cell recovery may be helpful for the early detection of agranulocytosis and prevention of serious infection. Further clinical studies are needed to elucidate the pathogenesis of delayed-onset postrituximab agranulocytosis.
